secwatch / observer
8-K filed December 5, 2024, 6:59 PM ET CIK 0001567892
M&A confidence high sentiment positive materiality 0.75

Keenova Therapeutics plc: M&A transaction — Mallinckrodt completes Therakos sale, uses $887.6M net proceeds to cut net debt >60%

Keenova Therapeutics plc

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

Keenova Therapeutics plc completed a disposition involving CVC Capital Partners Fund IX (affiliates Solaris Bidco Limited, Solaris IPCo Limited, Solaris US BidCo, LLC) for $925.0 million (closed 2024-11-29).

Action
disposition
Counterparty
CVC Capital Partners Fund IX (affiliates Solaris Bidco Limited, Solaris IPCo Limited, Solaris US BidCo, LLC)
Consideration
$925.0 million
Closing
2024-11-29
Exact text from the filing
to the conditions set forth in the Agreement, Purchasers agreed to acquire the Therakos Business from the Company (the “Therakos Transaction”) for a base purchase price of $925.0 million, subject to customary adjustments. On November 29, 2024, the Company completed the sale of the Therakos Business for total cash consideration of $887.6 million, which amount is
View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR
accession 0001567892-24-000045
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.